Olutasidenib, sold under the brand name Rezlidhia, is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. Olutasidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is taken by mouth.
{{Infobox drug | image = Olutasidenib.svg | image_class = skin-invert-image | width = | alt = | caption =
| pronounce = | tradename = Rezlidhia | Drugs.com = | MedlinePlus = | DailyMedID = Olutasidenib | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATC_prefix = L01 | ATC_suffix = XM03 | ATC_supplemental =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).